Go to the content. | Move to the navigation | Go to the site search | Go to the menu | Contacts | Accessibility

| Create Account

Pellati, Donatella (2008) Co-individuazione delle isoforme di mRNA per il recettore dei mineralcorticoidi (MR) e dell' enzima 11ß-idrossisteroide deidrogenasi in cellule e tessuti umani atipici, rispondenti all'aldosterone.
Studio particolareggiato in pazienti affetti da iperaldosteronismo primitivo e ricerca di mutazioni nel gene MR in una famiglia con diagnosi di pseudo-ipoaldosteronismo.
[Ph.D. thesis]

Full text disponibile come:

[img]
Preview
Documento PDF
5Mb

Abstract (english)

The steroid hormone aldosterone, that normally controls the urinary Na+/K+ balance, and the osmolarity in the kidney, colon, salivary and swab glands epithelial tissues, exerts also many different effects, by binding to the mineralocorticoid receptor (MR). This receptor binds both aldosterone and glucocorticoids (mostly cortisol) with approximately the same affinity. However, cortisol has a 1000-fold higher concentration in plasma than that of aldosterone. In its classical target tissues, the mineralocorticoid selectivity mainly depends on the enzymatic activity of the type 2 11ß-hydroxysteroid dehydrogenase (11ß -HSD2), which converts cortisol into inactive cortisone, a corticosteroid that doesn't bind to the MR. The human MR gene (hMR) maps on chromosome 4 and contains 8 coding exons, with the start of the open reading frame (ORF) in the exon 2, which gives a 984 aminoacid product. The untranslated exon 1, which exists in the two isoforms 1? and 1ß, may give rise, by alternative splicing, to the hMR? and hMRß mRNA variants. The hMRß seems to be expressed only in some tissues and cell types.
In 2001, two other hMR mRNA variants were described and they were called hMR?5 and hMR?5,6, because they lack the exon 5 or both exons 5 and 6, respectively. The hMR? transcript isoforms, first detected in the kidney, encode for a receptor which lack a fragment or the whole LBD domain, and they are both widely expressed among tissues, where they act as transcription factors that do not depend upon the ligand aldosterone.
In this work, I first demonstrated, by RT-PCR assays, the expression of hMR gene in spermatozoa, even though, in these cells, it was less detectable than in human mononuclear leukocytes (LMN). These important data were confirmed by immunofluorescence, in which the hMR protein was detectable in the middle piece and in the tail of the spermatozoa. These results may provide useful insight into mechanisms that can modify sperm motility in the presence of aldosterone in the milieu.
It is well known, from the scientific literature, that the activation of a number of genes, consequently to the specific MR-aldosterone interaction, may lead to the synthesis of some pro-inflammatory substances, in the heart, kidney, and in the vascular endothelium. In primary hyperaldosteronism, the presence of high aldosterone plasma levels may finally cause fibrosis in the same districts. The first steps of the inflammatory processes are characterized by a massive invasion of LMN, so, in the present research, I analyzed, by RT-PCR reactions, the expression of hMR gene variants in LMN from patients with Conn syndrome, and in both the normal adrenal cortex tissue, and in the adjacent adenoma producing aldosterone (APA) samples. I demonstrated a variable expression of the hMRß isoform, in comparison with the hMR? variant, which is homogeneously detectable in all the analyzed samples, and it was found that the hMRß mRNA was less expressed in the APA tissues, than in the normal adrenal tissue and in the LMN of the same patients.
In the same samples, I also verified the co-expression of mRNA for both the type 1 and 2 11ß-hydroxysteroid dehydrogenase (11ß-HSD 1 and 2). A very interesting outcome from this step of my study was the demonstration of the 11ß -HSD type 2 expression in LMN of most of the patients with primary aldosteronism, while the same mRNA was not detectable in LMN from healthy volunteers. These important results, if they are confirmed in a significantly greater number of patients, would provide more information in order to predict the presence of a primary aldosteronism itself.
In this work, I also analyzed, by RT-PCR, the expression of the above mentioned genes in five normal tissue samples from human larynx. Even in this case, the hMR?, hMRß and the 11ß-HSD type 2 mRNAs were all detectable in the larynx tissue, and so this can be considered as a novel tissue specifically responsive, in a genomic manner, to aldosterone by its interaction with MR. The meaning of this result will be investigate in the future.
Many human diseases depend upon a number of important mutations in almost all the hMR exons, causing type I pseudo-hypoaldosteronism (PHA I), which mimics the absence of aldosterone, even if it is synthesized in a great amount. In the last period of my work, I investigated the hMR gene for mutations in each exon, in a family with PHA I, composed by a newborn, that was identified as the case-control, and their parents. Since no important nucleotide substitutions was revealed in the analyzed coding regions, this family is probably affected by the renal variant of the above mentioned diseases, where the mutations involve the gene encoding for the epithelial sodium channels subunits in the kidney.


Statistiche Download - Aggiungi a RefWorks
EPrint type:Ph.D. thesis
Tutor:Prof. Colombo, Lorenzo
Supervisor:Prof. Armanini, Decio
Ph.D. course:Ciclo 20 > Scuole per il 20simo ciclo > BIOLOGIA E MEDICINA DELLA RIGENERAZIONE > ENDOCRINOLOGIA COMPARATA
Data di deposito della tesi:31 January 2008
Anno di Pubblicazione:31 January 2008
Key Words:MR= recettore dei mineralcorticoidi (Mineralocorticoid Receptor) 11ß-HSD= 11ß-idrossisteroide deidrogenasi (11ß -idroxysteroyde dehydrogenase) LMN= linfomonociti (Mononuclear Leukocytes) APA= adenoma del corticosurrene secernente aldosterone (Aldosterone Producing Adenoma) PHA= pseudo-ipoaldosteronismo (PseudoHypoAldosteronism) RT-PCR= reazione di polimerizzazione dei prodotti di retro-trascrizione (Retrotransciption-Polymerase Chain Reaction)
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/13 Endocrinologia
Struttura di riferimento:Dipartimenti > Dipartimento di Biologia
Codice ID:817
Depositato il:25 Nov 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L., Bhattacharya SK, Postlethwaite AE, Weber KT. 2003. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 93: e124-e135. Cerca con Google

2. Albertin G, Tortorella C, Malendowicz LK, Aragona F, Neri G, Nussdorfer GG. 2002. Human adrenal cortex and aldosterone secreting adenomas express both 11beta-hydroxysteroid dehydrogenase type 1 and type 2 genes. Int J Mol Med. 9: 495-498. Cerca con Google

3. Armanini D, Kuhnle U, Strasser T, Dorr H, Butenandt I, Weber PC, Stockigt JR, Pearce P, Funder JW. 1985a. Aldosterone-receptor deficiency in pseudohypoaldosteronism. New Eng J Med. 313: 1178-1181. Cerca con Google

4. Armanini D, Strasser T, Weber PC. 1985b. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol. 248: E388-390. Cerca con Google

5. Armanini D, Kuhnle U, Witzgall H, Tietze U, Saule H, Schroeter C, Strasser T, Butenandt I, Bidlingmaier F, Weber PC. 1986. The determination of mineralocorticoid receptors in human mononuclear leukocytes from patients with mineralocorticoid excess: physiological and pathological implications. Clin Exp Hypertens A. 8: 781-785. Cerca con Google

6. Armanini D, Fiore C, Pellati D. 2007. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension. 50: e69-70. Cerca con Google

7. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. 1987. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 237: 268-275. Cerca con Google

8. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth R, Greger R, Schutz G. 1998. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 95: 9424-9429. Cerca con Google

9. Berger S, Bleich M, Schmid W, Greger R, Schutz G. 2000. Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism. Kidney Int. 57: 1295-1298. Cerca con Google

10. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D, Cole TJ. 2001. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology. 142: 1587-1594. Cerca con Google

11. Bonny O, Rossier BC. 2002. Disturbances of Na/K balance: pseudohypoaldosteronism revisited. J Am Soc Nephrol. 13: 2399-2414. Cerca con Google

12. Booth RE, Johnson JP, Stockand JD. 2002. Aldosterone. Adv Phisiol Educ. 26: 8-20. Cerca con Google

13. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. 2000. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 58: 1219-1227. Cerca con Google

14. Brown NJ, Kumar S, Painter CA, Vaughan DE. 2002. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 40: 859-865. Cerca con Google

15. Calò LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D. 2004. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab. 89: 1973-1976. Cerca con Google

16. Colombo L, Dalla Valle L, Fiore C, Armanini D, Belvedere P. 2006. Aldosterone and the conquest of land. J Endocrinol Invest 29: 373-379. Cerca con Google

17. Connell J M C, Davies E. 2005. The new biology of aldosterone. J Endocrinol. 186: 1-20. Cerca con Google

18. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. 1998. Brain Corticosteroid receptor balance in health and disease. Endocr Rev. 19: 269-301. Cerca con Google

19. Fiore C., Sticchi D., Pellati D., Forzan S., Bonanni G., Bertoldo A., Massironi M., Calò L., Fassina A., Rossi G.P., Armanini D. 2006. Identification of mineralocorticoid receptor in human spermatozoa. Int J Mol Med. 18: 649-652. Cerca con Google

20. Fuller PJ, Young MJ. 2005. Mechanisms of Mineralocorticoid Action. Hypertension. 46: 1227-1235. Cerca con Google

21. Funder JW. 1997. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Ann Rev Med. 48: 231-240. Cerca con Google

22. Funder J.W. 2004. Aldosterone, mineralcorticoid receptors and vascular inflammation. Mol Cell Endocrinol. 217: 263-269. Cerca con Google

23. Funder JW. 2005a. Mineralocorticoid receptors: distribution and activation. Heart Failure Reviews. 10: 15-22. Cerca con Google

24. Funder JW. 2005b. The nongenomic action of aldosterone. Endocr Rev. 26: 313-321. Cerca con Google

25. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, Lifton RP. 1998. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 19:279-281. Cerca con Google

26. Geller DS, Zhang J, Zennaro M-C, Vallo-Boado A, Rodriguez-Soriano J, Furu L, Haws R, Metzger D, Botelho B, Karaviti L, Haqq AM, Corey H, Janssens S, Corvol P, Lifton RP. 2006. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol. 17: 1429-1436. Cerca con Google

27. Greenspan FS, Strewler GJ. 2000. Endocrinologia Generale e Clinica. Capitolo 10: Ipertensione Endocrina., Piccin Editore. Cerca con Google

28. Kardong KV. 2005. Vertebrati. Anatomia comparata, funzione, evoluzione. Ghiandola surrenale. McGraw-Hill Editore. Cerca con Google

29. Kuhnle U. 1997. At The Cutting Edge. Pseudohypoaldosteronism: mutation found, problem solved? Moll Cell Endocrinol. 133: 77-80. Cerca con Google

30. Le Menuet D, Viengchareun S, Penfornis P, Walker F, Zennaro MC, Lombes M. 2000. Targeted oncogenesis reveals a distinct tissue-specific utilization of alternative promoters of the human mineralocorticoid receptor gene in transgenic mice. J Biol Chem. 275: 7878-7886. Cerca con Google

31. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombès M. 2001. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 276:38911-38920. Cerca con Google

32. Le Menuet D, Viengchareun S, Muffat-Joly M, Zennaro MC, Lombes M. 2004. Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Mol Cell Endocrinol. 217: 127-136. Cerca con Google

33. Lifton RP, Gharavi AG, Geller DS. 2001. Molecular mechanisms of human hypertension. Cell. 104: 545-556. Cerca con Google

34. Lombes M, Edelman IS, Erlanger BF. 1989. Internal image properties of a monoclonal auto-anti-idiotypic antibody and its binding to aldosterone receptors. J Biol Chem. 264: 2528-2536. Cerca con Google

35. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. 1995. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 92: 175-182. Cerca con Google

36. Losel R, Wehling M. 2003. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 4: 46-56. Cerca con Google

37. Mattsson C, Young FW Jr. 2006. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2:198-208. Cerca con Google

38. Molina PE. 2004. Fisiologia Endocrina. Capitolo 6. Ghiandola surrenalica. McGraw-Hill Editore. Cerca con Google

39. Mortensen M, Woo P. 2006. Office steroid injections of the larynx. The Laryngoscope. 116: 1735-1739. Cerca con Google

40. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. 2006. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 91:2618-2623. Cerca con Google

41. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. 2005. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 16: 2906-2912. Cerca con Google

42. Ngarmukos C, Grekin RJ. 2001. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab. 281: E1122-1127. Cerca con Google

43. Nussey SS, Whitehead SA. 1999. Endocrinology. An integrated approach. BIOS Scientific Publishers Ltd. Cerca con Google

44. Oh YS, Warnock DG. 2000. Disorders of the epithelial Na+ channel in Liddle’s syndrome and autosomal recessive pseudohypoaldosteronism type 1. Exp Nephrol. 8: 320-325. Cerca con Google

45. Pascual-Le Tallec L, Demange C, Lombes M. 2004. Human mineralocorticoid receptor A and B protein forms produced by alternative translation sites display different transcriptional activities. Eur J Endocrinol. 150: 585-590. Cerca con Google

46. Pascual-Le Tallec L, Lombès M. 2005. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 19: 2211-2221. Cerca con Google

47. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes, and actions. Vitam Horm. 2003 66:29-76. Cerca con Google

48. Pitt B, Stier CT Jr, Rajagopalan S. 2003. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. Renin Angiotensin Aldosterone Syst. 4: 164-168. Cerca con Google

49. Pitt B. 2004. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 217: 53-58. Cerca con Google

50. Pujo L, Fagart J, Gary F, Papadimitriou DT, Claës A, Jeunemaître X, Zennaro M-C. 2007. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Human Mutation. 28: 33-40. Cerca con Google

51. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C. 1995. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 26: 971-978. Cerca con Google

52. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. 2002. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 143: 4828-4836. Cerca con Google

53. Rogerson FM, Dimopoulos N, Sluka P, Chu S, Curtis AJ, Fuller PJ. 1999. Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. J Biol Chem. 274: 36305-36311. Cerca con Google

54. Rogerson FM, Brennan FE, Fuller PJ. 2003. Dissecting mineralocorticoid receptor structure and function. J Steroid Biochem Mol Biol. 85: 389-396. Cerca con Google

55. Rogerson FM, Brennan FE, Fuller PJ. 2004. Mineralocorticoid receptor binding, structure and function. Mol Cell Endocrinol. 217: 203-212. Cerca con Google

56. Sartorato P, Lapeyraque A-L, Armanini D, Kuhnle U, Khaldi Y, Salomon R, Abadie V, Di Battista E, Naselli A, Racine A, Bosio M, Caprio M, Poulet-Young V, Chabrolle J-P, Niaudet P, De Gennes C, Lecornec M-H, Poisson E, Fusco AM, Loli P, Lombès M, Zennaro M-C. 2003. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Met. 88: 2508-2517. Cerca con Google

57. Sartorato P, Khaldi Y, Lapeyraque AL, Armanini D, Kuhnle U, Salomon R, Caprio M, Viengchareun S, Lombes M, Zennaro MC. 2004. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol Cell Endocrinol. 217: 119-125. Cerca con Google

58. Spindler B, Mastroberardino L, Custer M, Verrey F. 1997. Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia. Pflugers Arch. 434: 323-331. Cerca con Google

59. Stockand JD. 2002. New ideas about aldosterone signalling in epithelia. Am J Physiol Renal Physiol. 282: F559-576. Cerca con Google

60. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. 2002. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 161: 1773-1781. Cerca con Google

61. Wehling M, Armanini D, Strasser T, Weber PC. 1987. Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol. 252: E505-508. Cerca con Google

62. Wehling M, Kuhls S, Armanini D. 1989. Volume regulation of human lymphocytes by aldosterone in isotonic media. Am J Physiol. 257:E170-174. Cerca con Google

63. Wickert L, Selbig J, Watzka M, Stoffel-Wagner B, Schramm J, Bidlingmaier F, Ludwig M. 2000. Differential mRNA expression of the two mineralocorticoid receptor splice variants within the human brain: structure analysis of their different DNA binding domains. J Neuroendocrinol. 12:867-873. Cerca con Google

64. Williams JS, Williams GH. 2003. 50th Anniversary of Aldosterone. J Clin Endocrinol Metab. 88:2364-2372. Cerca con Google

65. Zennaro MC, Le Menuet D, Lombes M. 1996. Characterization of the human mineralocorticoid receptor gene 5'-regulatory region: evidence for differential hormonal regulation of two alternative promoters via nonclassical mechanisms. Mol Endocrinol. 10: 1549-1560. Cerca con Google

66. Zennaro MC, Farman N, Bonvalet JP, Lombes M. 1997. Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab. 82: 1345-1352. Cerca con Google

67. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombès M. 1998. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest. 101:1254-1260. Cerca con Google

68. Zennaro MC, Souque A, Viengchareun S, Poisson E, Lombes M. 2001. A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol Endocrinol. 15: 1586-1598. Cerca con Google

69. Zennaro MC, Lombes M. 2004. Mineralocorticoid resistance. Trends Endocrinol Metab. 15: 264-270. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record